Intellia filing spurs safety concerns over CRISPR drug

biopharmadive.com/news/intellia-crispr-liver-enzyme-adverse-event-ttr-cardiomyopathy/749231

Dive Brief:
- Intellia Therapeutics shares dropped 25% early Thursday after the gene-editing company disclosed that one patient in an ongoing Phase 3 trial had signs of liver stress.
- Lab tests showed the patient had grade 4 liver transaminase elevations that “appear to be resolving”…

This story appeared on biopharmadive.com, 2025-05-30 09:18:44.472000.
The Entire Business World on a Single Page. Free to Use →